Table 2.
Univariable analysis estimate by physical activity intensity at baseline
| Moderate intensity | Moderate High Intensity | Overall Activity | ||||
|---|---|---|---|---|---|---|
| regression coefficient |
p-value | regression coefficient | p-value | regression coefficient |
p-value | |
| Metabolic Factors | ||||||
| Body Mass Index (kg/m2) | −0.039 | 0.64 | −0.17 | 0.04 | −0.14 | 0.09 |
| HDL (mg/dL) | −0.19 | 0.02 | −0.01 | 0.87 | −0.15 | 0.08 |
| LDL (mg/dL) | −0.05 | 0.56 | −0.09 | 0.27 | −0.04 | 0.62 |
| Triglycerides(mg/dL) | −0.01 | 0.93 | −0.06 | 0.48 | −0.04 | 0.65 |
| HOMA-IR | 0.04 | 0.64 | −0.18 | 0.03 | −0.11 | 0.21 |
| Leptin | −0.10 | 0.22 | −0.34 | <0.001 | −0.28 | 0.00 |
| Cardiovascular measures | ||||||
| Carotid Distensibility (10-6*Newtons-1*m2) | 0.10 | 0.22 | −0.00 | 0.99 | 0.08 | 0.32 |
| Pericardial Fat (cm3) | −0.06 | 0.44 | −0.16 | 0.05 | −0.12 | 0.14 |
| Hyperemic VTI (cm) | 0.11 | 0.18 | 0.18 | 0.03 | 0.19 | 0.02 |
| Flow Mediated Dilation | −0.04 | 0.70 | −0.02 | 0.76 | −0.06 | 0.47 |
| Mean-mean IMT (mm) | −0.00 | 0.95 | 0.02 | 0.81 | 0.02 | 0.83 |
| Inflammation and Immune activation | ||||||
| Interleukin 6 (pg/mL) | −0.19 | 0.02 | −0.14 | 0.09 | −0.23 | <0.001 |
| hsCRP (µg/mL) | −0.20 | 0.02 | −0.13 | 0.12 | −0.20 | 0.02 |
| sCD163 (ng/ml) | 0.05 | 0.53 | −0.00 | 0.98 | −0.03 | 0.75 |
| sCD14 (ng/ml) | −0.16 | 0.06 | 0.08 | 0.34 | −0.02 | 0.79 |
| CD14+ CD16+ monocytes (%) | −0.05 | 0.59 | −0.13 | 0.12 | −0.15 | 0.07 |
| CD14dimCD16+ monocytes (%) | −0.12 | 0.16 | 0.02 | 0.83 | −0.06 | 0.47 |
Only variables with p <0.1 included; variables tested but not included: Demographics and clinical parameters (waist-hip ratio, glucose, insulin); inflammation and immune activation (D-dimer, CD4+CD38+HLADR+ T-cells, CD8+CD38+HLADR+ T-cells, TNF-α receptors I and II); cardiovascular measures (Framingham score and CAC score)